GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a gad65 vaccination trial

Diabetes Care

Volumn 37, Issue 6, 2014, Pages 1675-1680

  Krause, Stephanie ^a   Landherr, Ulrike ^b   Agardh, Carl David ^c   Hausmann, Simone ^a   Link, Katarina ^c   Hansen, Jesse M ^b   Lynch, Kristian F ^d   Powell, Michael ^e   Furmaniak, Jadwiga ^e   Rees Smith, Bernard ^e   Bonifacio, Ezio ^f   Ziegler, Anette G ^a,b   Lernmark, Åke ^c   Achenbach, Peter ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Forschergruppe Diabetes EV   (Germany)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e RSR LTD   (United Kingdom)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; AUTOANTIBODY; C PEPTIDE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMIC ACID DECARBOXYLASE 65 AUTOANTIBODY; HEMOGLOBIN A1C; IODINE 125; PLACEBO; UNCLASSIFIED DRUG; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; RECOMBINANT VACCINE;

ADULT; AGED; ANTIBODY AFFINITY; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LATENT AUTOIMMUNE DIABETES IN ADULT; LYMPHOCYTE FUNCTION; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SERUM; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 1; DISEASE COURSE; DOUBLE BLIND PROCEDURE; GLUCOSE INTOLERANCE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADULT; AGED; ALUM COMPOUNDS; AUTOANTIBODIES; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE INTOLERANCE; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; VACCINATION; VACCINES, SYNTHETIC;

EID: 84901452215     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1719     Document Type: Article

References (20)

1. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010;95:25-33
2. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013;309:2473-2479
3. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmunediabetes mellitus in adults with a non-insulindependent onset of disease. Diabetes 1993;42: 359-362
4. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005;19: 238-246
5. Agardh CD, Lynch KF, Palḿer M, Link K, Lernmark A. GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009;52:1363-1368
6. Ludvigsson J, FaresjoM, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-1920
7. Ludvigsson J, Krisky D, Casas R, et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012;366:433-442
8. Wherrett DK, Bundy B, Becker DJ, et al.; Type 1 Diabetes TrialNet GAD Study Group. Antigenbased therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011;378:319-327
9. Ludvigsson J, Hjorth M, Ch́eramy M, et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 2011;54:634-640
10. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004;114:589-597 (Pubitemid 39572109
11. Mayr A, Schlosser M, Grober N, et al. GAD autoantibody affinity and epitope specificity identify distinct immunization profiles in children at risk for type 1 diabetes. Diabetes 2007;56:1527-1533
12. Krause S, Chmiel R, Bonifacio E, et al. IA-2 autoantibody affinity in children at risk for type 1 diabetes. Clin Immunol 2012;145:224-229
13. Achenbach P, Lampasona V, Landherr U, et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009;52:1881-1888
14. Lampasona V, Schlosser M, Mueller PW, et al. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem 2011;57:1693-1702
15. Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005; 48:703-708
16. Coco G, Chen S, Powell M, et al. Analysis of the GAD65-GAD65 autoantibody interaction. Clin Chim Acta 2008;391:51-59
17. Adler K, Mueller DB, Achenbach P, et al. Insulin autoantibodies with high affinity to the bovine milk protein alpha casein. Clin Exp Immunol 2011;164:42-49
18. Bekris LM, Jensen RA, Lagerquist E, et al. GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination. Diabet Med 2007;24:521-526 (Pubitemid 46669313
19. Boettler T, Pagni PP, Jaffe R, et al. The clinical and immunological significance of GADspecific autoantibody and T-cell responses in type 1 diabetes. J Autoimmun 2013;44:40-48
20. Axelsson S, Ch'eramy M, Hjorth M, et al. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes. PLoS ONE 2011;6:e29008